Coeptis Therapeutics Inc (COEP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Coeptis Therapeutics Inc (COEP) has a cash flow conversion efficiency ratio of -0.165x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.15 Million) by net assets ($13.02 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Coeptis Therapeutics Inc (COEP) liquidity interval to measure how many days the company can operate on defensive assets alone.
Coeptis Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how Coeptis Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Coeptis Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Coeptis Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hanil Feed Co. Ltd
KQ:005860
|
-0.014x |
|
Flag Ship Acquisition Corp. Unit
NASDAQ:FSHPU
|
-0.006x |
|
Wrap Technologies Inc
NASDAQ:WRAP
|
-0.232x |
|
Samchem Holdings Bhd
KLSE:5147
|
-0.142x |
|
Engenco Ltd
AU:EGN
|
0.101x |
|
Sical Logistics Limited
NSE:SICALLOG
|
N/A |
|
United Palm Oil Industry Public Company Limited
BK:UPOIC
|
0.065x |
|
Dae Chang
KO:012800
|
-0.035x |
Annual Cash Flow Conversion Efficiency for Coeptis Therapeutics Inc (2004–2024)
The table below shows the annual cash flow conversion efficiency of Coeptis Therapeutics Inc from 2004 to 2024. For the full company profile with market capitalisation and key ratios, see Coeptis Therapeutics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $3.87 Million | $-6.65 Million | -1.719x | -97.56% |
| 2023-12-31 | $4.45 Million | $-3.88 Million | -0.870x | -7.86% |
| 2022-12-31 | $4.80 Million | $-3.88 Million | -0.807x | +57.75% |
| 2021-12-31 | $2.35 Million | $-4.49 Million | -1.910x | -413.23% |
| 2020-12-31 | $-5.14 Million | $-3.14 Million | 0.610x | +110.62% |
| 2019-12-31 | $15.69K | $-90.07K | -5.739x | +87.74% |
| 2018-12-31 | $17.93K | $-839.06K | -46.804x | -6291.45% |
| 2005-12-31 | $-551.66K | $-417.02K | 0.756x | +112.84% |
| 2004-12-31 | $-264.01K | $1.55 Million | -5.885x | -- |
About Coeptis Therapeutics Inc
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy tec… Read more